Xellia Pharma completes $13 million Hungarian plant expansion

Danish specialty pharma firm  Xellia Pharmaceuticals has completed the expansion of its new $13 million, Centralized Laboratory Services building at its Budapest, Hungary, manufacturing site.

The expansion strengthens the global anti-infective product capabilities with additional product stability and release testing expertise and capabilities, of Xellia, a Novo Group company.

The new 3,000m2, multi-story building accommodates state-of-the-art microbiology and chemical analytical laboratories, a product stability center and administrative offices. It is conveniently located next to Xellia’s current active pharmaceutical ingredient (APIs) manufacturing plant, which employs 250 people.